MANE Veradermics, Incorporated
Financings ·
Insiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales.
Veradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026.
Veradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses.
Veradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $62.1 million | $23.3 million |
| Net income (loss) | -$70.0 million | -$26.5 million |
| Cash from operations | -$71.6 million | -$23.7 million |
| Cash and equivalents | $21.8 million | $53.1 million |
| Short-term investments | $120.1 million | $0 |
Our latest story on this, dated Feb 5, 2026: "Veradermics completes $294.8 million IPO with full overallotment exercise". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 1, 2026: "Veradermics raises about $472 million in $100-a-share follow-on and warrant sale". The story links the filing or release it is based on. Read the story.
Veradermics, Incorporated trades under the ticker MANE on NYSE.
Veradermics, Incorporated is listed on NYSE.
The SEC Central Index Key (CIK) for Veradermics, Incorporated is 1827635. Its filings are on SEC EDGAR.
41,780,136 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Veradermics, Incorporated under United States.
Our directory classifies Veradermics, Incorporated as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Veradermics, Incorporated is US9229671048.
aibio.space lists Veradermics, Incorporated among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Veradermics, Incorporated reported a net loss of $70.0 million for the fiscal year ended Dec 31, 2025, and used $71.6 million of cash in operations, per its annual report to the SEC.
$62.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$819.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Veradermics, dated Aug 21, 2026: "Veradermics CEO, technical chief and two large holders sell shares in August". Insiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales. Source.
The quarterly report said the May follow-on offering of 4,420,358 shares, including 576,568 shares from the full underwriters' option, raised approximately $442.0 million gross. Source
The private-placement Form D reported $29,999,997 sold. Source
Veradermics closed a public offering of 3,843,790 common shares at $100.00 each and a concurrent private placement of pre-funded warrants for approximately $30.0 million gross. Source
The issuer and investors entered the private-placement purchase agreement. Source
Reported a financing. SEC Form S-1. Source
The annual report disclosed the completed 2025 Series C aggregate of $151 million. Source
The annual report disclosed Series B follow-on closings in January and February 2025. Source
The quarterly report dates the completed IPO to this day, with gross proceeds of approximately $294.8 million. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
The issuer effected a one-for-10.067 reverse split before the IPO. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
The private-offering notice reported $134,999,978 sold and $15 million remaining. Source
The Series C private-offering notice identifies this as its first sale date. Source
The private-offering notice reported $66,567,075 sold against a $75 million total. Source
The issuer entered a Series B purchase agreement and converted earlier notes into preferred stock. Source
At 2026-06-30, cash and equivalents were $319.333 million and current-asset marketable securities were $500.561 million. These are dated balances, not a current bank confirmation. Source
The quarterly report forecasts funding into 2030 under the current operating plan. It says assumptions could prove wrong and resources could run out earlier. Source
No unresolved substantial-doubt conclusion was found in the opened annual or quarterly report. Both give an affirmative assessment of ability to meet obligations for at least twelve months. Source
Derived second-quarter use was $14.490 million: half-year operating use of $35.658 million less first-quarter use of $21.168 million. This calculation is not a separately reported quarter-only cash-flow line. Source
A one-for-10.067 reverse split became effective on 2026-01-27 before the IPO. The opened source does not describe it as an exchange deficiency cure. Source
No open deficiency or delisting proceeding was verified in the opened history. The latest quarterly cover identifies the New York Stock Exchange. Source
The historical subscription price was $100.00 per common share. This is a financing term, not a current market quotation. Source
No. Almost all of the purchase price was paid at issuance, while the exercise price was $0.00001 per share. The later 13D reports cash exercises of the warrants. Source
No. It permits holder dispositions but says the issuer cannot predict whether or when holders may sell. It does not establish receipt of the selling holders proceeds by the issuer. Source
No specific class action or derivative action was verified. The quarterly legal disclosure is management assessment of materiality, not a universal no-litigation certification. Source
Deloitte & Touche LLP signed the latest annual audit and states service since 2023. Source
They are measured at different dates and may use different denominators. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio